Day 1Tuesday, September 1, 2026 - UTC+08:00

• Highlighting the strategic role of government programs in Singapore, Korea, Australia, and Japan in advancing RNA vaccine and therapeutic development, with a focus on funding, infrastructure, and fostering innovation ecosystems.

• Exploring collaborative frameworks between governments, academia, and industry to enhance RNA research, streamline clinical tri

• Evolution of RNA Therapeutics, Multiple Mechanisms and Approved Drugs
• Unique Features of RNAi Therapeutics
• Hepatic and extra-hepatic Delivery
• Challenges and Opportunities

• Highlighting Singapore’s Nucleic Acid Therapeutic Initiative (NATi) as a catalyst for regional collaboration, driving advancements in diverse RNA modalities such as mRNA, siRNA, and circular RNA through partnerships with APAC biotech, academic institutions, and industry leaders.

• Demonstrating Abogen's unique mRNA and LNP platform
• Sharing clinical data and progress of mRNA cancer vaccines
• Accelerating preclinical and clinical development of mRNA-based T cell engagers and in vivo CAR-T

Resistant cancers survive by deploying RNA strategies that regulate translation and stability, thereby modulating tumor persistence and immune signaling. By decoding these adaptive RNA programs, we can harness or modulate these regulatory circuits to control tumor adaptation and reduce the emergence of new resistance mechanisms. Leveraging multi-omic profiling and AI-guided modeling, this approach transforms stress-responsive RNA programs into programmable RNA therapeutics, including inducible translation circuits and targeted RNA modulators. Through this framework, RNA therapeutics can dynamically respond to tumor stress—enhancing resilience, precision, and adaptability—while exploiting the same code-control mechanisms tumors use to survive.

• Adaptive RNA Programs: Resistant tumors rewire coding and noncoding RNA programs to regulate translation and stability, enabling therapeutic persistence and immune evasion. These adaptive circuits can be therapeutically harnessed or modulated to control tumor persistence.
• Programmable RNA Therapeutics: By integrating multi-omic data and AI-guided modeling, stress-responsive translation circuits can be designed as programmable RNA therapeutics that dynamically respond to tumor adaptation, control protein output, and reduce the emergence of new resistance mechanisms.

• The COVID-19 pandemic demonstrated the promise of mRNA vaccines as a rapid-response platform, while also revealing critical gaps in global manufacturing capacity, equitable access, and timely deployment. To address these challenges and enhance preparedness for future pandemics, the International Vaccine Institute (IVI) is leading the development of DeCAFx—a Decentralized and Accelerated mRNA Vaccine Production System. DeCAFx is designed to enable scalable, regionally distributed, and time-sensitive mRNA vaccine manufacturing through modular infrastructure, standardized technologies, and pre-established technical partnerships.
• Aligned with global initiatives such as CEPI’s 100 Days Mission, DeCAFx aims to ensure vaccine production and distribution within weeks of pathogen identification. As part of this effort, IVI is advancing mRNA vaccine R&D through a global network of collaborators. These include prototype vaccines against Lassa fever (with SK bioscience) and Rift Valley fever (with Afrigen), platform validation using self-amplifying mRNA (with Karolinska Institute), and novel delivery systems such as microneedle patches (with QuadMedicine). IVI is also validating UTR-modified mRNA constructs (with Seoul National University) and evaluating an mRNA COVID-19 vaccine developed by Green Cross under KDCA support.
• Through DeCAFx, IVI aims to integrate technological innovation, regional manufacturing, and regulatory readiness to build a sustainable and equitable vaccine ecosystem capable of responding rapidly to future pandemic threats.

• Conventional in vitro transcription (IVT) has enabled the first wave of mRNA products, but important challenges remain for broader therapeutic use, including dsRNA impurities, excessive immunogenicity and/or reactogenicity, repeat-dosing limitations, scalability, and supply-chain complexity.
• This presentation will introduce Sensible Biotechnologies’ cell-based platform for mRNA design, manufacturing, and scale-up, and discuss how a cell-based production approach can enable high-purity mRNA with a favorable immunogenicity profile.
• It will also explore what this could mean for the future of mRNA therapeutics, particularly in applications where repeat dosing, high purity, low immunogenicity, and strong translational performance are critical.